Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by AUAUniversity and American Urological Association. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by AUAUniversity and American Urological Association or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists

1:14:46
 
Share
 

Manage episode 457369876 series 2497848
Content provided by AUAUniversity and American Urological Association. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by AUAUniversity and American Urological Association or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/41961 After participating in this CME activity, participants will be able to: 1. Assess the risk stratification of low, intermediate, and high risk NMIBC patients to appropriately guide treatment decisions. 2. Employ diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities. 3. Tailor treatment strategies based on individual patient characteristics and tumor biology to highlight the potential of personalized medicine in improving the management of NMIBC. 4. Identify new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies. 5. Properly manage adverse events associated with NMIBC treatment. Acknowledgements Support provided by an independent educational grant from: ImmunityBio, Inc. Merck & Co., Inc. UroGen Pharma, Inc.
  continue reading

383 episodes

Artwork
iconShare
 
Manage episode 457369876 series 2497848
Content provided by AUAUniversity and American Urological Association. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by AUAUniversity and American Urological Association or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/41961 After participating in this CME activity, participants will be able to: 1. Assess the risk stratification of low, intermediate, and high risk NMIBC patients to appropriately guide treatment decisions. 2. Employ diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities. 3. Tailor treatment strategies based on individual patient characteristics and tumor biology to highlight the potential of personalized medicine in improving the management of NMIBC. 4. Identify new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies. 5. Properly manage adverse events associated with NMIBC treatment. Acknowledgements Support provided by an independent educational grant from: ImmunityBio, Inc. Merck & Co., Inc. UroGen Pharma, Inc.
  continue reading

383 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play